SCMP Business16/11 13:00 (HKT)
Akeso shares plummet as Chinese firm’s cancer drug ivonescimab faces FDA setback

Shares in Hong Kong-listed Akeso plunged as much as 31.8 per cent on Monday morning after the US Food and Drug Administration (FDA) rejected its cancer drug application, raising investor worries over the company’s near-term commercial outlook. Ivonescimab, one of the most closely watched innovative